No Data
Genmab Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
H.C. Wainwright analyst Ram Selvaraju maintains $Genmab(GMAB.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 40.8% and a
Optimistic Buy Rating for Genmab on Promising Acasunlimab Clinical Data and Future Growth Potential
Genmab Announces Strategic Financial Updates
6-K: Report of foreign private issuer (related to financial reporting)
Morgan Stanley Maintains Equal-Weight on Genmab, Maintains $31 Price Target